Clinical Trial Update: Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of pevonedistat plus docetaxel in previously treated advanced non-small cell lung cancer was terminated with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Pevonedistat (pevonedistat)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2023-10-23